Study of Hemostasis in Case of Severe COVID-19
THROMBOVID
1 other identifier
observational
50
0 countries
N/A
Brief Summary
The COVID-19 outbreak has led to a significant increase in the number of patients admitted to intensive care for respiratory distress. Early data indicate a particularly high risk of thrombotic risk to viral lung disease, particularly in the most severe patients, with a particularly high incidence of pulmonary embolism. Catheter thrombosis and extra-renal purification filters are also abnormally common. These thrombotic complications could contribute to the mortality observed in this pathology. The introduction of early curative anticoagulation in the most severe patients has just been proposed by the perioperative hemostasis interest group Biologically, a significant proportion of patients hospitalized in intensive care have a marked biological inflammatory syndrome, associated with signs of activation of clotting (a frank increase in D-dimers). The presence of circulating anticoagulants is common. Interestingly, thrombocytosis, normally observed in such inflammatory syndromes, is absent. In this context, it seems legitimate to explore these patients from a hemostasis perspective to identify the factors that cause this thrombotic over-risk, in order to minimize the occurrence of these complications.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2020
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 16, 2020
CompletedStudy Start
First participant enrolled
April 17, 2020
CompletedFirst Posted
Study publicly available on registry
April 24, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 17, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2021
CompletedApril 24, 2020
April 1, 2020
1 year
April 16, 2020
April 21, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Platelet activation intensity with the occurrence of clinical thrombotic complications
Change of platelet activity from admission's day in intensive care unit to 2 days and 7 days
Interventions
3 extra blood samples at day 0, 2 and 7
Eligibility Criteria
Adult patients hospitalized in intensive care for severe COVID-19 infection
You may qualify if:
- Adult patient (\<18y)
- With a SARS-CoV-2 infection confirmed by RT-PCR
- Hospitalized in intensive care
You may not qualify if:
- Patients under guardianship/curator
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Tacquard C, Mouriaux C, Delabranche X, Bourdon C, Eckly A, Magnenat S, Sattler L, Gachet C, Mertes PM, Hechler B, Mangin PH. Platelet dysfunction and thrombus instability in flow conditions in patients with severe COVID-19. Thromb Res. 2023 Jan;221:137-148. doi: 10.1016/j.thromres.2022.11.004. Epub 2022 Nov 8.
PMID: 36376109DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 16, 2020
First Posted
April 24, 2020
Study Start
April 17, 2020
Primary Completion
April 17, 2021
Study Completion
May 1, 2021
Last Updated
April 24, 2020
Record last verified: 2020-04